Literature DB >> 27861313

Is Trough Concentration of Vancomycin Predictive of the Area Under the Curve? A Clinical Study in Elderly Patients.

Anis Bel Kamel1, Laurent Bourguignon, Micaela Marcos, Michel Ducher, Sylvain Goutelle.   

Abstract

BACKGROUND: Current guidelines suggest that vancomycin trough concentrations (Cmin) between 15 and 20 mg/L should be achieved to optimize vancomycin exposure and effect. The objective of this study was to analyze the correlation between vancomycin Cmin and the area under the concentration-time curve (AUC) and assess the ability to predict an AUC target of 400 mg·h/L based on Cmin.
METHODS: A retrospective analysis of vancomycin therapeutic drug monitoring data collected in 95 elderly patients treated with intermittent intravenous vancomycin was performed. For each patient, individual pharmacokinetic parameters of vancomycin and AUC24 were estimated from concentration measurements using a Bayesian approach. The relationship between vancomycin Cmin and AUC was studied using global and local correlation analysis as well as logistic regression with Receiver Operating Characteristic curve analysis.
RESULTS: The overall correlation between AUC24 and Cmin was significant but moderate (R = 0.51). When vancomycin Cmin was greater than 15 mg/L, the corresponding AUC24 was >400 mg·h/L in 95% of cases. However, AUC24 values >400 mg·h/L were obtained with Cmin < 15 mg/L in more than 30% of the cases. The logistic regression analysis identified a Cmin value of 10.8 mg/L as the optimal predictor of AUC24 > 400 mg·h/L.
CONCLUSIONS: The results of this study indicate that the recommended target range of 15-20 mg/L for vancomycin Cmin seems acceptable for controlling vancomycin exposure, although a value of approximately 11 mg/L appears to be optimal and may be safer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27861313     DOI: 10.1097/FTD.0000000000000359

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  10 in total

1.  Cystatin C and/or creatinine-based estimated glomerular filtration rate for prediction of vancomycin clearance in long-stay critically ill patients with persistent inflammation, immunosuppression and catabolism syndrome (PICS): a population pharmacokinetics analysis.

Authors:  Jingjing Huang; Xiaoli Wang; Chenxia Hao; Wanhua Yang; Weixia Zhang; Jialin Liu; Hongping Qu
Journal:  Intern Emerg Med       Date:  2021-03-16       Impact factor: 3.397

2.  Methods of Therapeutic Drug Monitoring to Guide Vancomycin Dosing Regimens: Trough Concentration versus Ratio of Area Under the Curve to Minimum Inhibitory Concentration.

Authors:  Ariane Du Sault; Marc Parent; Chantale Simard
Journal:  Can J Hosp Pharm       Date:  2022-04-04

3.  Population Pharmacokinetics of Vancomycin in Kidney Transplant Recipients: Model Building and Parameter Optimization.

Authors:  Kui-Fen Ma; Yi-Xi Liu; Zheng Jiao; Jun-Hao Lv; Ping Yang; Jian-Yong Wu; Si Yang
Journal:  Front Pharmacol       Date:  2020-10-06       Impact factor: 5.810

4.  Two Innovative Approaches to Optimize Vancomycin Dosing Using Estimated AUC after First Dose: Validation Using Data Generated from Population PK Model Coupled with Monte-Carlo Simulation and Comparison with the First-Order PK Equation Approach.

Authors:  Qingxia Liu; Huiping Huang; Baohua Xu; Dandan Li; Maobai Liu; Imam H Shaik; Xuemei Wu
Journal:  Pharmaceutics       Date:  2022-05-07       Impact factor: 6.525

Review 5.  Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice.

Authors:  Fawzy Elbarbry
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

6.  Therapeutic Drug Monitoring of Vancomycin in Adult Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia or Pneumonia.

Authors:  Ryan Marko; Julia Hajjar; Vanessa Nzeribe; Michelle Pittman; Vincent Deslandes; Nadia Sant; Juthaporn Cowan; Kwadwo Kyermentang; Tim Ramsay; Sheryl Zelenitsky; Salmaan Kanji
Journal:  Can J Hosp Pharm       Date:  2021

7.  Heaping the Pelion of Vancomycin on the Ossa of Methicillin-resistant Staphylococcus aureus: Back to Basics in Clinical Care and Guidelines.

Authors:  William F Wright; Sarah C J Jorgensen; Brad Spellberg
Journal:  Clin Infect Dis       Date:  2021-05-18       Impact factor: 20.999

8.  Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations.

Authors:  Joaquim F Monteiro; Siomara R Hahn; Jorge Gonçalves; Paula Fresco
Journal:  Pharmacol Res Perspect       Date:  2018-07

9.  Development of a decision flowchart to identify the patients need high-dose vancomycin in early phase of treatment.

Authors:  Ryo Yamaguchi; Hiroko Kani; Takehito Yamamoto; Takehiro Tanaka; Hiroshi Suzuki
Journal:  J Pharm Health Care Sci       Date:  2022-01-04

Review 10.  Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Kazuaki Matsumoto; Kazutaka Oda; Kensuke Shoji; Yuki Hanai; Yoshiko Takahashi; Satoshi Fujii; Yukihiro Hamada; Toshimi Kimura; Toshihiko Mayumi; Takashi Ueda; Kazuhiko Nakajima; Yoshio Takesue
Journal:  Pharmaceutics       Date:  2022-02-23       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.